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wileyonlinelibrar1. Introduction
Understanding and recapitulating angiogenesis in vitro
and in vivo is of critical interest to the fields of tissue
engineering and therapeutic angiogenesis. Current suc-
cesses in tissue engineering are significantly limited by the
inability to generate functional vasculature, which is
necessary because diffusion is insufficient to meet the
metabolic demands of larger tissues. Engineering vascula-
ture isalsoof interest for the treatmentof ischemicdiseases,such as peripheral artery disease (PAD) and other related
conditions.[1]
To address the need for vascularization, researchers
have explored both cell and growth factor delivery from an
appropriate scaffold.[2] In thiswork, we utilize an approach
to therapeutic vascularization wherein endothelial cells
(ECs) are delivered with supportive stromal cells in a
biomaterial system that supports neovascularization
in vivo.[3–5] Several studies have demonstrated the impor-
tance of stromal support in the formation of lumen-
containing vessel structures in angiogenesis assays in
vitro and in inosculation in vivo.[3,4,6–9] Natural hydrogel
materials, such as fibrin, collagen, and Matrigel, have been
widely used in this approach by our laboratory[3,9–12] and
many others[5,13–17] because they are well known to
support angiogenesis and vasculogenesis. However, such
natural materials have many inherent limitations,DOI: 10.1002/mabi.201400161y.com
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and processing approaches, the potential for immunoge-
nicity, and undefined biological functionalities. Conse-
quently, many investigators have pursued the use of
synthetic materials with tailored biological functionalities
as cell delivery vehicles.[18–21] Such materials offer the
potential for enhanced control over cell function and allow
investigation of the multiple roles of the extracellular
matrix (ECM) on vascularization.
Peptide-functionalized poly(ethylene glycol) (PEG) hy-
drogel systems have been widely exploited to investigate
the role of distinct biological signals in modulating cell
invasion and in complex processes, such as vascularization,
in vitro.[22–33] In these systems, PEG is typically function-
alized with peptide sequences susceptible to cleavage by
cell-derived matrix metalloproteases (MMPs) and with
RGD, a minimal integrin-binding domain isolated from
fibronectin that has been ubiquitously tethered to a
variety of biomaterials to render them adhesive. The
majority of early studies in this area utilized a MMP-
cleavable peptide composed of a collagen-derived cleavage
sequence, GPQG#IWGQ (cleavage site indicated by #), with
flanking regions on either side to facilitate crosslinking via
thiol or amine chemistries. Cell invasion and vasculariza-
tion were greatly improved in these gels as compared to
non-degradable controls.[26,30,33] More recent studies have
used more rapidly degraded MMP-cleavable peptides for
in vitro studies of cell migration and vascularization with
promising results.[25,29,34,35] Others have tunedmechanical
properties of the construct to indirectly alter the extent of
proteolysis needed to support robust vascularization.[29,30]
As a whole, these prior studies suggest functionalized PEG
gels are a viable option to support vascularization and
warrant additional study.
Despite the wealth of studies elucidating the role of
matrix mechanics and degradation in vasculogenesis in
PEG hydrogels in vitro, the role of these properties in
promotingvascularization invivo is lessclear. Instead,most
efforts to date have focused primarily on utilizing PEG
matrices for cell-demanded release of various factors.[36]
Additionally, many of the materials utilized for promoting
vascularization via growth factor delivery require fabrica-
tion ex vivo.[30,32,37–40] Though researchers have incorpo-
rated both GPQG#IWGQ[30,32,37–39,41] and a more rapidly
degradedpeptide,VPMS#MRGG,[35,42] intomatricesutilized
in vivo, variations in vascularization between these two
variants has not been investigated directly. Several studies
have demonstrated PEG hydrogels support the recruitment
of host vasculature upon hydrogel delivery with growth
factors[30,32,35,37–39,41] or growth factors with pancreatic
islets[35,42] or MSCs.[40]
The goal of this work was to investigate the roles of gel
mechanical properties and susceptibility to proteolysis in
vascular morphogenesis in vitro and in vivo, and therebyMacromol. Biosci. 20
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translation-focused in vivo applications.We fabricated PEG
hydrogels via Michael-type addition of PEG macromers
and cysteine-containing MMP-sensitive and adhesive
peptides, and then characterized their ability to support
vessel network formation fromECs and stromal fibroblasts.
Two MMP-sensitive peptides were used for crosslinking,
GPQG#IWGQ (slow degradation) and VPMS#MRGG (more
rapid degradation). RGD was used as an adhesive moiety
to facilitate cell attachment to the PEG gels. Materials
were characterized and subsequently investigated for their
capacity to support vascular morphogenesis over a period
of two weeks in vitro and in subcutaneous pockets on
the dorsal flank of SCID mice in vivo.2. Experimental Section
2.1. Cell Isolation and Culture
Human umbilical vein endothelial cells (HUVECs, henceforth
referred to as ECs) were isolated according to a previously
established protocol.[43] ECs were cultured in supplemented
endothelial growth medium (EGM-2, Lonza, Walkersville, MD) at
37 8C and 5% CO2 and used at passage 3. Normal human lung
fibroblasts (NHLFs, Lonza) were cultured in M199 (Invitrogen
Corporation, Carlsbad, CA) with 10% fetal bovine serum (FBS),
1% penicillin/streptomycin (Mediatech, Manassas, VA), and 0.5%
gentamicin (Invitrogen) at 37 8C and 5% CO2 and used prior to
passage 15. Cells were cultured in monolayers until reaching 80%
confluency and passaged with 0.05% trypsin–EDTA (Invitrogen).2.2. PEG Hydrogel Formation
Hydrogels were formed via a Michael-type addition reaction of
4-arm PEG vinyl sulfone (PEG-VS; 20 kDa, JenKem USA, Allen, TX)
with a combination of thiol-containing adhesive and protease-
sensitive peptides by modifying a published protocol.[44] To alter
gel degradation rates, we selected two different peptides that
are cleaved at different rates by several MMPs. In addition to
proteolytic susceptibility, we altered gel solids content to investi-
gate the role of initialmechanical properties on vascularization. To
prepare the gels, PEG-VS was dissolved in HEPES (50mM, pH 8.4,
supplemented with growth factors from endothelial medium
bullet kit) at the appropriate concentration to produce gels of 3.5
or 5% (w/v) total solids content. The adhesive peptide (CGRGDS,
Genscript, Piscataway, NJ) was added to the PEG solution at
10mg mL1 in HEPES to yield a final adhesive site density upon
gelation of 500mM and the solution was reacted 30min at room
temperature. Following conjugation of RGD, bis-cysteine-contain-
ing crosslinking peptides were added in HEPES such that -SH and
-VSgroupswerepresentat a1:1molar ratio.Gelswerepolymerized
with one of two peptides, Ac-GCRD-GPQG#IWGQ-DRCG-NH2 or
Ac-GCRD-VPMS#MRGG-DRCG-NH2 (Genscript, cleavage site indi-
cated by #). Henceforth, gels polymerized with GPQG#IWGQ
and VPMS#MRGG will be referred to as PEG-G and PEG-V gels,
respectively. After mixing, precursor solutions (3.5% PEG-G, 5%14, 14, 1368–1379
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1370PEG-G, 3.5%PEG-V, and5%PEG-V)were polymerized for 1h at 37 8C
in Teflonmolds for rheology experiments or in sterile 1-ml syringes
with the needle end cut off for all other experiments.[45] After
polymerization, gels were transferred to medium or PBS, as
appropriate. All gels were formed under aseptic conditions from
precursors that were filtered through a 0.22mm syringe filter.2.3. Mechanical and Physical Characterization of PEG
Gels
Bulk mechanical properties were characterized via parallel plate
rheology on swollen gels. Following polymerization in Teflon
molds, 100mL gels were swollen overnight in PBS at 37 8C.
Measurements were obtained on an AR G2 rheometer (TA
Instruments, New Castle, DE) equipped with a Peltier stage and
an8mmgeometry.BothsurfaceswerecoatedwithP800sandpaper
(3M, St. Paul, MN) and the gap was adjusted to apply a constant
0.1N force to prevent slip during measurement. For each gel,
a 5min time sweep was followed by a frequency sweep from
0.1 to 10Hz at 5% strain and then a strain sweep from 0.1 to
50% at 1Hz. Reported shear storage modulus (G0) values are
the average over the linear viscoelastic region of the frequency
sweep.
The equilibrium volumetric swelling ratio was also obtained
for each gel type. Cell-free gels 50ml in volume were polymerized
in cut off syringes, as described above, and swollen at 37 8C in
PBS for 48h. At this point, each gel was weighed, frozen, and
lyophilized, to give values for the wet and dry weight of each gel.
The volumetric swelling ratio was calculated from the mass
swelling ratio according to a previously described method:[46]Q ¼ 1þ rpolymer
rsolvent
ðq 1Þ ð1Þwhere q is the mass swelling ratio (wet weight/final dry weight),
rpolymer is the polymer density (1.07 gmL
1 for PEG), and rsolvent
is the density of the buffer (1 gmL1).
Cell-mediated bulk hydrogel degradation was assessed by
monitoring the swelling ratio of 50ml gels containing 106 ECs
mL1 and 106 NHLFs mL1. Gels were cultured at 37 8C and 5% CO2
up to 14 d. The swelling ratio was determined as for gels without
cells.2.4. Dextran Release from PEG Hydrogels
Thebulk transportofdextranthroughthehydrogelswasquantified
as described previously[47] to probe the relative ease of diffusion of
macromolecular species through different hydrogel formulations.
Acellular hydrogels were prepared under aseptic conditions with
5mg of 70 kDa Texas red-conjugated dextran (Life Technologies)
incorporated in each 50ml gel. Hydrogels were incubated in sterile
PBS at 37 8C and the supernatant was aseptically collected
and replaced with fresh PBS at 1, 3, 6, 12, 24, and 72h after
polymerization. After 72h, gels were digested with 40 IU
collagenase (Worthington Biochemical, Lakewood, NJ) in PBS to
release any remaining dextran. The supernatants from each time
point and the degraded gels were measured with a Fluoroskan
Ascent FL (Thermo Scientific) plate reader at Ex:560/Em:620. TheMacromol. Biosci. 201
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to a standard curve of dextran in PBS.2.5. Vasculogenesis Assay in PEG Hydrogels
ECs were fluorescently labeled via retroviral transduction with a
gene encoding mCherry (Clonteck, Mountain View, CA) as
previously described.[9] Lipofectamine 2000 (Life Technologies)
wasused to transfect PhoenixAmphocells (Orbigen, SanDiego, CA)
with a plasmid encoding for mCherry. Viral supernatant was
collected after 48h, passed through a 0.45mm syringe filter and
supplementedwith 5mgmL1 Polybrene (EMDMillipore, Billerica,
MA) prior to incubation with EC for 6 h. The mediumwas changed
to EGM-2 and cells were cultured overnight. Transduction was
repeatedvia another roundofviral infection the followingday, and
the ECs were then grown to confluence and used directly in the
vasculogenesis assay. Constructs were polymerized in 50mL
aliquots using cut off syringes. Cell mixtures in a 1:1 ratio of ECs
and NHLFs were added for a total of 105 cells/gel. Cell-seeded
constructswere cultured in fully supplemented EGM-2 in a 12-well
plate with the media changed every other day. At 7 and 14 d post-
fabrication, gels from each condition were washed several times
with PBS and then fixed with formalin prior to imaging. Low
magnification fluorescent imageswere obtained of vessel network
formation in each gel. Each gel was imaged at five locations in the
interior of the gel using an Olympus IX81 spinning disk confocal
microscope (Olympus, Center Valley, PA) with a Hammamatsu
(Bridgewater, NJ) camera. Average total network length was
determinedas describedpreviously[48] for each conditionusing the
automated Angiogenesis Module in Metamorph Premier Software
(Molecular Devices, Inc., Sunnyvale, CA).
Tomonitor the effect of inhibition ofMMPor plasmin-mediated
degradation on organization into vascular networks, a subset of
experiments was conducted with GM6001 in dimethyl sulfoxide
(DMSO) or aprotinin added to both the gel precursor solution and
the culture medium. As a control, additional constructs were
treated with the vehicle alone (DMSO). A broad-spectrum MMP
inhibitor, GM6001 (EMD Chemicals, San Diego, CA), was added at
10mM and the serine protease inhibitor aprotinin (Sigma) was
addedat2.2mM, asused inpreviouswork fromour lab.[10] Inhibitors
were replenishedwith eachmedia change. At 7 d post-fabrication,
gels were fixed then imaged at low magnification.2.6. PEG Hydrogel Implantation in SCID Mice and
Laser Doppler Perfusion Imaging
All animal procedures were performed following a protocol
approved by the University of Michigan Committee on Use and
Care of Animals in accordance with NIH guidelines for the use of
laboratory animals. Male six- to eight-week-old C.B.-17/SCID
mice (Taconic Labs, Hudson, NY) were used for all experiments.
Anesthetic/analgesic cocktail of 95mgkg1 ketamine (MWI Vet,
Boise, ID), 9.5mgkg1 xylazine (MWI Vet), and 0.059mgkg1
buprenorphine (Bedford Laboratories, Bedford, OH) was delivered
to eachmousevia intraperitoneal injection.Thedorsalflankof each
mouse was cleared of fur by shaving followed by the application
of a depilatory agent (Nair, Fisher Scientific, Pittsburgh, PA). The4, 14, 1368–1379
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Fremont, CA) andwipeddownwith an alcohol pad. Implants (n¼ 5
per condition) were prepared as described above. Prior to initiation
of the procedure, cell mixtures in a 1:1 ratio of ECs:NHLFs were
preparedandaliquoted toyielda totalof3millioncellsper injection
sample (300ml total volume, or 10 million total cells/ml). As prior
studies from our lab using fibrin[49] and from others using PEG-VS
gelswithoutVEGF[37]have illustratedthatminimalvascularization
is seen in acellular controls, all implants contained cells and gel
conditions alone were varied. Just prior to implantation, the bis-
cysteine peptide in HEPES was combined with the PEGþRGD
solution, the mediumwas aspirated from the top of the cell pellet,
and the cellswere resuspended in the gel precursor. Solutionswere
immediately injected subcutaneously on the dorsal flank of the
mouse, with two implants placed per animal. Animals were kept
stationary for 5min to allow for implant gelation and then
subjected to laser Doppler perfusion imaging (LDPI, Perimed AB,
Sweden). Each mouse was imaged in triplicate. Mice were then
placed in fresh cages for recovery. At Days 4, 7, and 14, mice were
anesthetizedwith the cocktail described above and then subjected
again to LDPI. Surgeons were not blinded to the experimental
conditions.2.7. Dextran Tracer Injection and Implant Removal
Implants were retrieved after 7 or 14 d following systemic
administration of a 70 kDa Texas Red-conjugated dextran (lex/em
of 595/615nm, Invitrogen), used to assess inosculation of the
transplanted cells within the implant with host vessels as
described in previouswork from our laboratory.[49] Following LDPI
at each retrieval time point, each mouse was placed in a restraint
device and 200mL of a 5mgmL1 dextran solution in PBS was
injected via the tail vein. After injection,miceweremoved to fresh
cages and the tracer was allowed to circulate systemically for
10min. Animals were then euthanized and the implants were
surgically excised.2.8. Implant Processing and Histology
All explants were fixed 1h in 4% PFA and then moved to 0.4% PFA
overnight. Followingfixation, sampleswere rinsed several times in
cold PBS and then transferred to a sterile solution of 30% sucrose in
PBS for 48 h at 4 8C. At this time, explants were transferred to a
mixture containing two parts 30% sucrose in PBS and one part
OCT embedding compound (Andwin Scientific, Schaumburg, IL) for
another 24h at 4 8C. Explants were then transferred to 100% OCT
and kept another 24h at 4 8C. Each sample was then finally
embedded in 100% OCT in a disposable plastic mold (Fisher
Scientific) and flash frozen on the surface of liquid nitrogen. Frozen
sectionswere generated from each sample by the histology core at
the University of Michigan School of Dentistry.
Sections were stained for human CD31 using both immunohis-
tochemistry (IHC) and immunofluorescence (IF). After staining,
sections were imaged using an Olympus IX81 spinning disk
confocalmicroscopewith a DP2-Twain (Olympus) color camera for
visualizing IHC stained slides and a Hammamatsu camera for
visualizing fluorescent-stained sections.Macromol. Biosci. 20
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and rinsed with PBS. Sections were incubated with 0.05% trypsin–
EDTA for 10min at 37 8C for antigen retrieval and washed with DI
water then TBS-T. Sections were blocked 5min using a peroxidase
blocking solution (Dako EnVision System-HRP (DAB) kit, Dako,
Carpinteria, CA). Primary antibody (human anti-mouse CD31,
Dako) was diluted 1:50 in TBS-T and applied to slides. Following
incubation overnight at 4 8C, slides were treated for 30min with
the HRP-conjugated anti-mouse secondary antibody provided in
the kit. Prior to imaging, slides were mounted with xylene
mounting medium (Fisher Scientific) and a #1 coverslip. One set
of sections was imaged without any counterstain; the remaining
sections were counterstained with hematoxylin and eosin and
then imaged.
For IF staining, slideswerewarmed for 20min then rinsed three
times with PBS. Sections were blocked with 5% goat serum in PBS
to eliminate non-specific protein binding. The primary antibody
(human CD31; Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
was diluted 1:50 in 5% goat serum and added to samples for an
overnight incubation at 4 8C. Following three washes with PBS,
the secondary antibody (Alexa Fluor 488 goat anti-rabbit,
Invitrogen) was added to tissues at a 1:100 dilution and tissues
were incubated 30min at room temperature. The unbound
antibody was removed by three additional washes with PBS.
Slides were then mounted with VectaShield (Vector Labs,
Burlingame, CA) and covered with a #1 glass coverslip prior to
imaging. Representative images were chosen for each condition.
Using sections stained with hCD31 via IHC, the number of
blood vessels derived from transplanted human cells were
quantified manually. Structures were considered blood vessels if
they exhibited a rim of positive hCD31 stain and a hollow lumen.
The average number of vessels per field of view in each sectionwas
determined by averaging the values obtained by two independent
evaluators for at least five images per animal taken at 40.2.9. Statistics
All statistical analyses were performed using GraphPad Prism
(GraphPad Software, La Jolla, CA). Data are from n3 and are
reported as mean SEM. Analyses were performed with one or
two-way ANOVA followed by Bonferroni’s multiple comparison
post-tests. Statistical significance was assumed when p<0.05.3. Results and Discussion
3.1. Gelation and Mechanical Characterization
PEG-based hydrogels were prepared by reacting PEG-VSwith
cysteine-containing adhesive peptides and bis-cysteine con-
taining crosslinking peptides (see schematic in Figure 1A).
Gelation occurred within 5min and crosslinking was
complete within 1h, as assessed with shear rheology (data
not shown). Mechanical characterization of pre-swollen
gels composed of 3.5 and 5% w/v and each degradable
peptide via shear rheology revealed that the storage
modulus (G0) did not vary as a function of the crosslinking14, 14, 1368–1379
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Figure 1. A) Hydrogels were formed via Michael type addition of cysteine containing RGD and MMP-degradable peptides (GCRD-
GPQG#IWGQ-DRCG and GCRD-VPMS#MRGG-DRCG, cleavage at #) with 4-arm PEG vinyl sulfone. Gels are susceptible to MMP-
mediated degradation but not hydrolysis. B) Hydrogels were polymerized, swollen, and their mechanical properties tested via shear
rheology. All gels tested contain 500mM RGD. Significantly different from 3.5% G. #Significantly different from 3.5% V. p<0.05, one-way
ANOVA followed by Bonferroni post-tests. C) Volumetric swelling ratios of equilibrated acellular gels. Significantly different from 3.5% G.
#Significantly different from 3.5% V. p<0.05, one-way ANOVA followed by Bonferroni post-tests. D) Swelling ratios of hydrogels containing
cells changed significantly (indicated with ) from Day 1 to 14 in 3.5% and 5% V gels. p<0.05, two-way ANOVA followed by Bonferroni
post-tests.
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1372peptide used, but increased significantly with increasing
gel solids content (Figure 1B). Measurement of the
volumetric swelling ratio for each gel type showed that
the 3.5% gels swelled significantly more than 5% gels
(Figure 1C). Extent of swelling did not significantly differ
between PEG-G and PEG-V gels. As indicated by shear
modulus and swelling ratio, changing solids content, but
not peptide identity, significantly affected bulk network
structure. These results corroborate the invariance of bulk
mechanical properties to changing peptide identity dem-
onstrated in another recent study.[50]
The swelling ratios of hydrogels containing cells were
also obtained to characterize if cell-mediated remodeling of
thegelnetworksvariedasa functionof crosslinkingpeptide
identity (Figure 1D). At Day 1, swelling ratio values for each
condition matched those obtained for gels without cells.
Over 14 d, PEG-V gels with cells underwent significant
changes in swelling behavior, which were not observed in
PEG-G gels. These data suggest the encapsulated ECs and
fibroblasts more rapidly degrade PEG-V than PEG-G gels,Macromol. Biosci. 201
 2014 WILEY-VCH Verlag GmbHin agreement with the published comparative rates of
degradation of the two peptides by MMPs 1 and 2.[25,51]
However, since cells can both degrade the hydrogels and
deposit new ECM proteins, changes in swelling ratio are
only evidence of remodeling. Constructs without cells did
not undergo significant changes in swelling over the course
of 14 d (data not shown), implying proteolysis, and not
hydrolysis mediates the observed effects.3.2. Dextran Release from Hydrogels
Cumulative release profiles of fluorescent dextran were
generated for each hydrogel, and the datawere normalized
to the total mass of dextran entrapped (Figure 2A).
Experimental data were fit to the following equation,
corresponding to a first-order exponential approxima-
tion[47] of Fickian diffusion through a planar slab,[52] using
nonlinear least squares regression:4, 14, 1
& Co.M ¼ Mo þ ðMf MoÞ½1 eKt ð2Þ368–1379
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Figure 2. A) To assess bulk transport within the hydrogels, the release of 70 kDa Texas red-conjugated dextran entrapped within
polymerized gels was measured over 72 h. B) Rate constants, K, were determined by fitting release profiles to a first-order exponential
approximation. No significant differences were found across gel formulations. p>0.05, sum-of-squares F-test.
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PEG-G, 3.5% PEG-V, and 5% PEG-V gels (R2: 0.91, 0.89, 0.80,
and0.85, respectively). Fromthesedata, the rateconstant,K,
was calculated for all hydrogel formulations, and a sum-
of-squares F-test demonstrated no significant differences
between release rates across gel formulation (Figure 2B).
Thus, these data suggest the diffusive transport of large
molecules does not vary significantly across the different
gel formulations, despite differences in bulk mechanical
properties.3.3. Vascular Network Formation in PEG Gels
In Vitro
Co-encapsulation of ECs and NHLFs in PEG-peptide hydro-
gels resulted in the formation of primitive capillary-like
networks in all conditions over a period of two weeks
(Figure 3A). The extent of vascularization, as measured by
total network length, differed significantly based on gel
identity (Figure 3B). Hydrogels with an initially high
crosslink density (5w/v%gels) supported vascular network
formation, as measured by total network length, to a
significantly lower degree over two weeks in culture than
those gels with a lower initial crosslink density (3.5w/v%
gels) in PEG-G and PEG-V gels. This observed decrease is
consistentwith previous studies from our laboratory using
PEG-collagen hydrogels,[47] and from another study that
showed crosslinking density attenuated radial sprouting
from endothelial and smooth muscle cell spheroids
encapsulated in PEGDA-derived hydrogels.[29] Attenuated
sprouting in the more crosslinked 5w/v% gels was not
attributed to changes indiffusive transport, as thediffusion
of dextran tracers, as assessed above,was the same inall gelMacromol. Biosci. 20
 2014 WILEY-VCH Verlag Gmwww.MaterialsViews.comformulations. As a whole, these studies suggest initial
hydrogel mechanical properties are an important modula-
tor of vascular morphogenesis, even in matrices that cells
can remodel.
The role of peptide identity on vascular network
formation was also characterized (Figure 3). Network
length at Day 7 was comparable between PEG-G and
PEG-V gels at matching w/v%. By Day 14, PEG-V gels
appeared qualitatively to support increased vessel network
formation compared to Day 7 values and to PEG-G gels.
However, the differences between Days 7 and 14 and
between matched PEG-G and PEG-V gels were not statisti-
cally significant (Figure3B), despitemeasureddifferences in
swelling of PEG-G and PEG-V gels in the presence of cells
that suggest the PEG-V gels are more rapidly remodeled.
This may result from a delay between the onset of
degradation and matrix vascularization, an idea corrobo-
ratedby thequalitative increase invascularizationof PEG-V
versus PEG-G gels at Day 14. Alternately, the increased
swelling of PEG-V gels in the presence of cells may be a
direct consequence of the fibroblasts rather than the ECs,
and thus may not be a good proxy for assessing local
matrix degradation around the sprouting tubules.
Vascular network formationwithin these hydrogelswas
also verified to be MMP-dependent based on the observa-
tion that morphogenesis was attenuated in the presence
of the broad-spectrum MMP inhibitor, GM6001 (Figure 4).
ECs remained round and did not organize into tubules in
the presence of GM6001 in all gel formulations tested,
regardless of peptide identity or hydrogel w/v%. By
contrast, the addition of either a DMSO vehicle or the
serine protease inhibitor aprotinin had no significant
effects. Fibroblast migration in similar gels has also been14, 14, 1368–1379
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Figure 3. Vasculogenesis in vitro was monitored in PEG hydrogels of different w/v% and cross-linked with either of two degradable
peptides. A) mCherry tagged ECs co-encapsulated with unlabeled fibroblasts organized into vascular networks in gels, and were imaged
after 7 or 14 d (scale bars¼ 200mm). B) Quantification of the total lengths of the vessel networks showed that the extent of vascularization
was significantly higher in lower w/v% gels and slightly increased at later time points in PEG-V gels. Significant differences were found via
one-way ANOVA followed by Bonferroni post-tests and are indicated according to the following symbols: compared to 5% PEG-G at 7 d,
#compared to 5% PEG-V at 7 d, ^compared to 5% PEG-G at 14 d, and % compared to 5% PEG-V at 14 d, p<0.05.
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1374shown to depend on MMPs,[26,53] but these data demon-
strate that MMPs are also required for vascularization in
these gels.3.4. Non-Invasive Perfusion Measurement of PEG
Hydrogels Implanted In Vivo
PEG hydrogels containing ECs and NHLFs were injected
subcutaneously on the dorsal flank of SCID mice and the
vascularization by the implanted cells and subsequent
inosculation with the host were monitored over 14 d.
LDPI was used to monitor perfusion through the implant
non-invasively (Figure 5). For all conditions, perfusion
qualitatively increased over the course of the experiment.
LDPI data suggest the rate of implant perfusion differs as a
function of peptide identity, with significant increases in
perfusion seen between 0 and 4 d for PEG-V gels only. InMacromol. Biosci. 201
 2014 WILEY-VCH Verlag GmbHcontrast, PEG-G gels appear to undergo less pronounced
and slower changes in perfusion, particularly between 0
and 4 d, as assessed by LDPI.3.5. Histological Analysis of Harvested Tissues
Vessels formed from transplanted human cells in all PEG
constructs, and the resulting vessels were shown to
inosculate with the host vasculature within 7 d after
delivery of the cellswithin the gels. Upon retrieval from the
subcutaneous space, the implanted PEG-based constructs
exhibitedvisible redness (Figure6). Cryosections stained for
human CD31 and H&E demonstrated that all four of the
hydrogel compositions tested supported the transplanted
humanECs (Figure7A).ThesehumanCD31-stainedsections
showed the presence of lumen-containing networks
(arrows) containing host erythrocytes, indicating the4, 14, 1368–1379
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Figure 4. Vasculogenesis was monitored in vitro in gels of different w/v% and crosslinking peptides in untreated control gels and in the
presence of 10mM GM6001, DMSO, or 2.2mM aprotinin in gels and culture media. mCherry tagged-ECs co-encapsulated with unlabeled
fibroblasts organized into vascular networks in control gels and in gels containing DMSO or aprotinin, but not in gels containing GM6001.
Constructs were fixed and imaged after 7 d (scale bars¼ 200mm).
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www.mbs-journal.deformation of a perfused vascular network from the
transplanted human ECs for all gel formulations tested
(Figure 7A). Systemic administration of a fluorescent
dextrantracer furtherconfirmedinosculationofhostvessels
with the neovessels of human cell origin that form within
the PEG gels. Imaging of cryosectioned implants stained
with hCD31 from tracer-injected animals revealed dextran-
perfusedvessels (red) linedwithhumanCD31þ cells (green)
in all gel types (Figure 8). All implants contained a clearly
delineated border between mouse tissue and the PEG gel,
suggesting that the ingrowth of host connective tissue into
these PEG gels is relatively slow. Local gel degradation and
cell-mediatedmatrix deposition in the periphery of vessels,
illustrated by the presence of eosinophilic matrix around
hCD31-stained vasculature, were observed.
Qualitatively, differences in vasculature were observed
across conditions.However,quantificationofvesseldensity
showed the extent of vascularization differed significantly
only between 3.5 and 5% PEG-V implants harvested at 7 dMacromol. Biosci. 20
 2014 WILEY-VCH Verlag Gmwww.MaterialsViews.com(Figure 7B). The increase in vascularization at Day 7 for 5%
PEG-V gels was unexpected given the results of the in vitro
studies. Thisdifferencemaybeduetodifferences in levelsof
protease activity and in protease identity in the two
scenarios. In vivo, proteases are secreted by a variety of cell
types, including interstitial and inflammatory cells in
addition to ECs.[54] Our in vitromodel only accounts for the
contribution of endothelial and stromal support cells. Thus,
matrices may be remodeled more rapidly in vivo, which
mayalter the initialmechanical environment that supports
vascularization. As others have suggested previously in
the context of cell migration,[26] excessive degradation of
less crosslinked matrices may impair the ability of cells
to generate traction upon matrix cleavage. These data
demonstrate that the set of matrix cues determined to
be optimal for vascular morphogenesis in vitro may not be
the same ones necessary to maximize vascularization in
vivo, andmotivate further investigation of thesematerials
in vivo.14, 14, 1368–1379
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Figure 5. Laser Doppler perfusion imaging was used to non-invasively quantify blood flow after subcutaneous injection of gel constructs. A)
Upper images show implant location on mouse. Lower images are LDPI heat maps indicating degree of perfusion. B) Quantification of
relative perfusion shows differences between gel constructs. Statistically significant effects for both day and gel compositionwere found by
two-way ANOVA. Statistically significant increases in perfusionwere observed fromDays 0 to 4 for 3.5% PEG-V () and 5% PEG-V (#). p<0.05
two-way ANOVA followed by Bonferroni post-tests.
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13764. Conclusion
In this study, we demonstrated PEG hydrogels functional-
ized with adhesive and MMP-degradable peptides support
the formationof vascularnetworks fromencapsulated cells
both invitroand invivo.Byvarying the solids contentof the
hydrogels and the identity of the protease-sensitive cross-Macromol. Biosci. 201
 2014 WILEY-VCH Verlag GmbHlinking peptides, we investigated the respective roles of gel
mechanical properties and the kinetics of proteolysis on
network formation. Our in vitro results showed that
increasing solids content to increase gel mechanical
properties significantly attenuated vascular morphogene-
sis in 3D, but that the formation of vessel networks was
quantitatively similar for the two different crosslinking4, 14, 1368–1379
& Co. KGaA, Weinheim www.MaterialsViews.com
Figure 6. Macroscopic images of implants harvested at Days 7 and 14. Visible redness within implants suggested implant vasculature
inosculated with host vessels in all gel constructs after implantation.
Figure 7. A) IHC and H&E staining of cryosections from implants retrieved after 7 or 14 d in vivo. Sections were stained for human CD31,
counterstained with H&E, and then imaged at 40 (scale bars¼ 50 mm). Arrows point to representative hCD31-positive vessels. B) Vessel
density was quantified from stained sections and compared with a two-way ANOVA followed by Bonferroni post-tests. There was a
significantly higher density of vessels in the 5% PEG-V gels compared to the 3.5% PEG-V gels at 7 d.
Protease-Sensitive PEG Hydrogels Regulate Vascularization . . .
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Figure 8. Red fluorescent 70-kDa dextran was administered systemically to mice prior to implant retrieval on Day 7. Following fixation and
cryosectioning, tissues were stained for human CD31 (green) and imaged. Red present within hCD31þ structures indicated inosculation of
host and implant vasculature (scale bars¼ 25mm).
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1378peptides studied. Our in vivo results showed that all gel
formulations supported the formation of perfused vascula-
ture from transplanted cells and vessel density was not
attenuated inmore highly crosslinked or in less degradable
gels, suggesting the in vivo environment may be more
permissive to vascularization. This may be of particular
interest in designing therapies for clinical use, and under-
scores the limitations of in vitro systems to fully recapitu-
late the more clinically relevant in vivo environment.
Overall, we have demonstrated that an injectable PEG-
based synthetic material that polymerizes in situ is well
suited as a vehicle for cell-based vascularization therapies
and may represent a viable alternative to more invasive
treatment options for ischemic diseases.Acknowledgments: The authors gratefully acknowledge financial
support for this study from the National Heart, Lung, and Blood
Institute of the National Institutes of Health under award
numbers R01HL085339 and R01HL118259. The authors would
also like to thank Chris Strayhorn at the Histology Core at the
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